Aspirin	B:C0004057
Suppresses	O
Growth	O
in	O
PI3K	O
-	O
Mutant	O
Breast	O
Cancer	I:C0678222
by	O
Activating	O
AMP	O
-	I:C2350345
activated	I:C2350345
protein	I:C2350345
kinase	I:C2350345
and	O
Inhibiting	O
mTORC1	O
Signaling	O
.	O

Aspirin	O
Suppresses	O
Growth	B:C0018270
in	O
PI3K	O
-	O
Mutant	O
Breast	O
Cancer	I:C0678222
by	O
Activating	O
AMP	O
-	I:C2350345
activated	I:C2350345
protein	I:C2350345
kinase	I:C2350345
and	O
Inhibiting	O
mTORC1	O
Signaling	O
.	O

Aspirin	O
Suppresses	O
Growth	O
in	O
PI3K	B:C1335212
-	O
Mutant	O
Breast	O
Cancer	I:C0678222
by	O
Activating	O
AMP	O
-	I:C2350345
activated	I:C2350345
protein	I:C2350345
kinase	I:C2350345
and	O
Inhibiting	O
mTORC1	O
Signaling	O
.	O

Aspirin	O
Suppresses	O
Growth	O
in	O
PI3K	O
-	O
Mutant	B:C0678941
Breast	O
Cancer	I:C0678222
by	O
Activating	O
AMP	O
-	I:C2350345
activated	I:C2350345
protein	I:C2350345
kinase	I:C2350345
and	O
Inhibiting	O
mTORC1	O
Signaling	O
.	O

Aspirin	O
Suppresses	O
Growth	O
in	O
PI3K	O
-	O
Mutant	O
Breast	B:C0678222
Cancer	I:C0678222
by	O
Activating	O
AMP	O
-	I:C2350345
activated	I:C2350345
protein	I:C2350345
kinase	I:C2350345
and	O
Inhibiting	O
mTORC1	O
Signaling	O
.	O

Aspirin	O
Suppresses	O
Growth	O
in	O
PI3K	O
-	O
Mutant	O
Breast	O
Cancer	I:C0678222
by	O
Activating	O
AMP	B:C2350345
-	I:C2350345
activated	I:C2350345
protein	I:C2350345
kinase	I:C2350345
and	O
Inhibiting	O
mTORC1	O
Signaling	O
.	O

Aspirin	O
Suppresses	O
Growth	O
in	O
PI3K	O
-	O
Mutant	O
Breast	O
Cancer	I:C0678222
by	O
Activating	O
AMP	O
-	I:C2350345
activated	I:C2350345
protein	I:C2350345
kinase	I:C2350345
and	O
Inhibiting	O
mTORC1	B:C2975458
Signaling	O
.	O

Despite	O
the	O
high	O
incidence	O
of	O
oncogenic	B:C0029016
mutations	O
in	O
PIK3CA	O
,	O
the	O
gene	O
encoding	I:C3839127
the	O
catalytic	O
subunit	I:C0600499
of	O
PI3K	O
,	O
PI3K	O
inhibitors	O
have	O
yielded	O
little	O
clinical	O
benefit	I:C1333602
for	O
breast	O
cancer	I:C0678222
patients	O
.	O

Despite	O
the	O
high	O
incidence	O
of	O
oncogenic	O
mutations	B:C0026882
in	O
PIK3CA	O
,	O
the	O
gene	O
encoding	I:C3839127
the	O
catalytic	O
subunit	I:C0600499
of	O
PI3K	O
,	O
PI3K	O
inhibitors	O
have	O
yielded	O
little	O
clinical	O
benefit	I:C1333602
for	O
breast	O
cancer	I:C0678222
patients	O
.	O

Despite	O
the	O
high	O
incidence	O
of	O
oncogenic	O
mutations	O
in	O
PIK3CA	B:C1335212
,	O
the	O
gene	O
encoding	I:C3839127
the	O
catalytic	O
subunit	I:C0600499
of	O
PI3K	O
,	O
PI3K	O
inhibitors	O
have	O
yielded	O
little	O
clinical	O
benefit	I:C1333602
for	O
breast	O
cancer	I:C0678222
patients	O
.	O

Despite	O
the	O
high	O
incidence	O
of	O
oncogenic	O
mutations	O
in	O
PIK3CA	O
,	O
the	O
gene	B:C3839127
encoding	I:C3839127
the	O
catalytic	O
subunit	I:C0600499
of	O
PI3K	O
,	O
PI3K	O
inhibitors	O
have	O
yielded	O
little	O
clinical	O
benefit	I:C1333602
for	O
breast	O
cancer	I:C0678222
patients	O
.	O

Despite	O
the	O
high	O
incidence	O
of	O
oncogenic	O
mutations	O
in	O
PIK3CA	O
,	O
the	O
gene	O
encoding	I:C3839127
the	O
catalytic	B:C0600499
subunit	I:C0600499
of	O
PI3K	O
,	O
PI3K	O
inhibitors	O
have	O
yielded	O
little	O
clinical	O
benefit	I:C1333602
for	O
breast	O
cancer	I:C0678222
patients	O
.	O

Despite	O
the	O
high	O
incidence	O
of	O
oncogenic	O
mutations	O
in	O
PIK3CA	O
,	O
the	O
gene	O
encoding	I:C3839127
the	O
catalytic	O
subunit	I:C0600499
of	O
PI3K	B:C0044602
,	O
PI3K	O
inhibitors	O
have	O
yielded	O
little	O
clinical	O
benefit	I:C1333602
for	O
breast	O
cancer	I:C0678222
patients	O
.	O

Despite	O
the	O
high	O
incidence	O
of	O
oncogenic	O
mutations	O
in	O
PIK3CA	O
,	O
the	O
gene	O
encoding	I:C3839127
the	O
catalytic	O
subunit	I:C0600499
of	O
PI3K	O
,	O
PI3K	B:C0044602
inhibitors	O
have	O
yielded	O
little	O
clinical	O
benefit	I:C1333602
for	O
breast	O
cancer	I:C0678222
patients	O
.	O

Despite	O
the	O
high	O
incidence	O
of	O
oncogenic	O
mutations	O
in	O
PIK3CA	O
,	O
the	O
gene	O
encoding	I:C3839127
the	O
catalytic	O
subunit	I:C0600499
of	O
PI3K	O
,	O
PI3K	O
inhibitors	B:C0014432
have	O
yielded	O
little	O
clinical	O
benefit	I:C1333602
for	O
breast	O
cancer	I:C0678222
patients	O
.	O

Despite	O
the	O
high	O
incidence	O
of	O
oncogenic	O
mutations	O
in	O
PIK3CA	O
,	O
the	O
gene	O
encoding	I:C3839127
the	O
catalytic	O
subunit	I:C0600499
of	O
PI3K	O
,	O
PI3K	O
inhibitors	O
have	O
yielded	O
little	O
clinical	B:C1333602
benefit	I:C1333602
for	O
breast	O
cancer	I:C0678222
patients	O
.	O

Despite	O
the	O
high	O
incidence	O
of	O
oncogenic	O
mutations	O
in	O
PIK3CA	O
,	O
the	O
gene	O
encoding	I:C3839127
the	O
catalytic	O
subunit	I:C0600499
of	O
PI3K	O
,	O
PI3K	O
inhibitors	O
have	O
yielded	O
little	O
clinical	O
benefit	I:C1333602
for	O
breast	B:C0678222
cancer	I:C0678222
patients	O
.	O

Recent	O
epidemiologic	B:C0002783
studies	I:C0002783
have	O
suggested	O
a	O
therapeutic	O
benefit	O
from	O
aspirin	O
intake	O
in	O
cancers	O
harboring	O
oncogenic	O
PIK3CA	I:C0044602

Recent	O
epidemiologic	O
studies	I:C0002783
have	O
suggested	O
a	O
therapeutic	O
benefit	O
from	O
aspirin	B:C0004057
intake	O
in	O
cancers	O
harboring	O
oncogenic	O
PIK3CA	I:C0044602

Recent	O
epidemiologic	O
studies	I:C0002783
have	O
suggested	O
a	O
therapeutic	O
benefit	O
from	O
aspirin	O
intake	O
in	O
cancers	B:C0006826
harboring	O
oncogenic	O
PIK3CA	I:C0044602

Recent	O
epidemiologic	O
studies	I:C0002783
have	O
suggested	O
a	O
therapeutic	O
benefit	O
from	O
aspirin	O
intake	O
in	O
cancers	O
harboring	O
oncogenic	B:C0044602
PIK3CA	I:C0044602

Here	O
,	O
we	O
show	O
that	O
mutant	B:C0678941
PIK3CA	O
-	O
expressing	O
breast	O
cancer	I:C1512505
cells	I:C1512505
have	O
greater	O
sensitivity	O
to	O
aspirin	O
-	O
mediated	O
growth	O
suppression	O
than	O
their	O
wild	O
-	I:C1883559
type	I:C1883559
counterparts	O
.	O

Here	O
,	O
we	O
show	O
that	O
mutant	O
PIK3CA	B:C0044602
-	O
expressing	O
breast	O
cancer	I:C1512505
cells	I:C1512505
have	O
greater	O
sensitivity	O
to	O
aspirin	O
-	O
mediated	O
growth	O
suppression	O
than	O
their	O
wild	O
-	I:C1883559
type	I:C1883559
counterparts	O
.	O

Here	O
,	O
we	O
show	O
that	O
mutant	O
PIK3CA	O
-	O
expressing	B:C0017262
breast	O
cancer	I:C1512505
cells	I:C1512505
have	O
greater	O
sensitivity	O
to	O
aspirin	O
-	O
mediated	O
growth	O
suppression	O
than	O
their	O
wild	O
-	I:C1883559
type	I:C1883559
counterparts	O
.	O

Here	O
,	O
we	O
show	O
that	O
mutant	O
PIK3CA	O
-	O
expressing	O
breast	B:C1512505
cancer	I:C1512505
cells	I:C1512505
have	O
greater	O
sensitivity	O
to	O
aspirin	O
-	O
mediated	O
growth	O
suppression	O
than	O
their	O
wild	O
-	I:C1883559
type	I:C1883559
counterparts	O
.	O

Here	O
,	O
we	O
show	O
that	O
mutant	O
PIK3CA	O
-	O
expressing	O
breast	O
cancer	I:C1512505
cells	I:C1512505
have	O
greater	O
sensitivity	O
to	O
aspirin	B:C0004057
-	O
mediated	O
growth	O
suppression	O
than	O
their	O
wild	O
-	I:C1883559
type	I:C1883559
counterparts	O
.	O

Here	O
,	O
we	O
show	O
that	O
mutant	O
PIK3CA	O
-	O
expressing	O
breast	O
cancer	I:C1512505
cells	I:C1512505
have	O
greater	O
sensitivity	O
to	O
aspirin	O
-	O
mediated	O
growth	B:C0007595
suppression	O
than	O
their	O
wild	O
-	I:C1883559
type	I:C1883559
counterparts	O
.	O

Here	O
,	O
we	O
show	O
that	O
mutant	O
PIK3CA	O
-	O
expressing	O
breast	O
cancer	I:C1512505
cells	I:C1512505
have	O
greater	O
sensitivity	O
to	O
aspirin	O
-	O
mediated	O
growth	O
suppression	B:C0007613
than	O
their	O
wild	O
-	I:C1883559
type	I:C1883559
counterparts	O
.	O

Here	O
,	O
we	O
show	O
that	O
mutant	O
PIK3CA	O
-	O
expressing	O
breast	O
cancer	I:C1512505
cells	I:C1512505
have	O
greater	O
sensitivity	O
to	O
aspirin	O
-	O
mediated	O
growth	O
suppression	O
than	O
their	O
wild	B:C1883559
-	I:C1883559
type	I:C1883559
counterparts	O
.	O

Aspirin	B:C0004057
decreased	O
viability	O
and	O
anchorage	O
-	I:C1515979
independent	I:C1515979
growth	I:C1515979
of	O
mutant	O
PIK3CA	O
breast	O
cancer	I:C1512505
cells	I:C1512505
independently	O
of	O
its	O
effects	O
on	O
COX	O
-	I:C0387583
2	I:C0387583
and	O
NF	O
-	I:C0079904
κB	I:C0079904
.	O

Aspirin	O
decreased	O
viability	B:C0007620
and	O
anchorage	O
-	I:C1515979
independent	I:C1515979
growth	I:C1515979
of	O
mutant	O
PIK3CA	O
breast	O
cancer	I:C1512505
cells	I:C1512505
independently	O
of	O
its	O
effects	O
on	O
COX	O
-	I:C0387583
2	I:C0387583
and	O
NF	O
-	I:C0079904
κB	I:C0079904
.	O

Aspirin	O
decreased	O
viability	O
and	O
anchorage	B:C1515979
-	I:C1515979
independent	I:C1515979
growth	I:C1515979
of	O
mutant	O
PIK3CA	O
breast	O
cancer	I:C1512505
cells	I:C1512505
independently	O
of	O
its	O
effects	O
on	O
COX	O
-	I:C0387583
2	I:C0387583
and	O
NF	O
-	I:C0079904
κB	I:C0079904
.	O

Aspirin	O
decreased	O
viability	O
and	O
anchorage	O
-	I:C1515979
independent	I:C1515979
growth	I:C1515979
of	O
mutant	B:C0678941
PIK3CA	O
breast	O
cancer	I:C1512505
cells	I:C1512505
independently	O
of	O
its	O
effects	O
on	O
COX	O
-	I:C0387583
2	I:C0387583
and	O
NF	O
-	I:C0079904
κB	I:C0079904
.	O

Aspirin	O
decreased	O
viability	O
and	O
anchorage	O
-	I:C1515979
independent	I:C1515979
growth	I:C1515979
of	O
mutant	O
PIK3CA	B:C0044602
breast	O
cancer	I:C1512505
cells	I:C1512505
independently	O
of	O
its	O
effects	O
on	O
COX	O
-	I:C0387583
2	I:C0387583
and	O
NF	O
-	I:C0079904
κB	I:C0079904
.	O

Aspirin	O
decreased	O
viability	O
and	O
anchorage	O
-	I:C1515979
independent	I:C1515979
growth	I:C1515979
of	O
mutant	O
PIK3CA	O
breast	B:C1512505
cancer	I:C1512505
cells	I:C1512505
independently	O
of	O
its	O
effects	O
on	O
COX	O
-	I:C0387583
2	I:C0387583
and	O
NF	O
-	I:C0079904
κB	I:C0079904
.	O

Aspirin	O
decreased	O
viability	O
and	O
anchorage	O
-	I:C1515979
independent	I:C1515979
growth	I:C1515979
of	O
mutant	O
PIK3CA	O
breast	O
cancer	I:C1512505
cells	I:C1512505
independently	B:C1299583
of	O
its	O
effects	O
on	O
COX	O
-	I:C0387583
2	I:C0387583
and	O
NF	O
-	I:C0079904
κB	I:C0079904
.	O

Aspirin	O
decreased	O
viability	O
and	O
anchorage	O
-	I:C1515979
independent	I:C1515979
growth	I:C1515979
of	O
mutant	O
PIK3CA	O
breast	O
cancer	I:C1512505
cells	I:C1512505
independently	O
of	O
its	O
effects	O
on	O
COX	B:C0387583
-	I:C0387583
2	I:C0387583
and	O
NF	O
-	I:C0079904
κB	I:C0079904
.	O

Aspirin	O
decreased	O
viability	O
and	O
anchorage	O
-	I:C1515979
independent	I:C1515979
growth	I:C1515979
of	O
mutant	O
PIK3CA	O
breast	O
cancer	I:C1512505
cells	I:C1512505
independently	O
of	O
its	O
effects	O
on	O
COX	O
-	I:C0387583
2	I:C0387583
and	O
NF	B:C0079904
-	I:C0079904
κB	I:C0079904
.	O

We	O
ascribed	O
the	O
effects	O
of	O
aspirin	B:C0004057
to	O
AMP	O
-	I:C2350345
activated	I:C2350345
protein	I:C2350345
kinase	I:C2350345
(	O
AMP	O
-	I:C2350345
activated	I:C2350345
protein	I:C2350345
kinase	I:C2350345
)	O
activation	O
,	O
mTORC1	O
inhibition	O
,	O
and	O
autophagy	O
induction	O
.	O

We	O
ascribed	O
the	O
effects	O
of	O
aspirin	O
to	O
AMP	B:C2350345
-	I:C2350345
activated	I:C2350345
protein	I:C2350345
kinase	I:C2350345
(	O
AMP	O
-	I:C2350345
activated	I:C2350345
protein	I:C2350345
kinase	I:C2350345
)	O
activation	O
,	O
mTORC1	O
inhibition	O
,	O
and	O
autophagy	O
induction	O
.	O

We	O
ascribed	O
the	O
effects	O
of	O
aspirin	O
to	O
AMP	O
-	I:C2350345
activated	I:C2350345
protein	I:C2350345
kinase	I:C2350345
(	O
AMP	B:C2350345
-	I:C2350345
activated	I:C2350345
protein	I:C2350345
kinase	I:C2350345
)	O
activation	O
,	O
mTORC1	O
inhibition	O
,	O
and	O
autophagy	O
induction	O
.	O

We	O
ascribed	O
the	O
effects	O
of	O
aspirin	O
to	O
AMP	O
-	I:C2350345
activated	I:C2350345
protein	I:C2350345
kinase	I:C2350345
(	O
AMP	O
-	I:C2350345
activated	I:C2350345
protein	I:C2350345
kinase	I:C2350345
)	O
activation	O
,	O
mTORC1	B:C2975459
inhibition	O
,	O
and	O
autophagy	O
induction	O
.	O

We	O
ascribed	O
the	O
effects	O
of	O
aspirin	O
to	O
AMP	O
-	I:C2350345
activated	I:C2350345
protein	I:C2350345
kinase	I:C2350345
(	O
AMP	O
-	I:C2350345
activated	I:C2350345
protein	I:C2350345
kinase	I:C2350345
)	O
activation	O
,	O
mTORC1	O
inhibition	B:C1519312
,	O
and	O
autophagy	O
induction	O
.	O

We	O
ascribed	O
the	O
effects	O
of	O
aspirin	O
to	O
AMP	O
-	I:C2350345
activated	I:C2350345
protein	I:C2350345
kinase	I:C2350345
(	O
AMP	O
-	I:C2350345
activated	I:C2350345
protein	I:C2350345
kinase	I:C2350345
)	O
activation	O
,	O
mTORC1	O
inhibition	O
,	O
and	O
autophagy	B:C0004391
induction	O
.	O

In	O
vivo	O
,	O
oncogenic	B:C0029016
PIK3CA	O
-	O
driven	O
mouse	O
mammary	O
tumors	I:C1458155
treated	O
daily	O
with	O
aspirin	O
resulted	O
in	O
decreased	O
tumor	O
growth	O
kinetics	O
,	O
whereas	O
combination	O
therapy	O
of	O
aspirin	O
and	O
a	O
PI3K	O
inhibitor	O
further	O
attenuated	O
tumor	O
growth	O
.	O

In	O
vivo	O
,	O
oncogenic	O
PIK3CA	B:C0044602
-	O
driven	O
mouse	O
mammary	O
tumors	I:C1458155
treated	O
daily	O
with	O
aspirin	O
resulted	O
in	O
decreased	O
tumor	O
growth	O
kinetics	O
,	O
whereas	O
combination	O
therapy	O
of	O
aspirin	O
and	O
a	O
PI3K	O
inhibitor	O
further	O
attenuated	O
tumor	O
growth	O
.	O

In	O
vivo	O
,	O
oncogenic	O
PIK3CA	O
-	O
driven	O
mouse	B:C0025929
mammary	O
tumors	I:C1458155
treated	O
daily	O
with	O
aspirin	O
resulted	O
in	O
decreased	O
tumor	O
growth	O
kinetics	O
,	O
whereas	O
combination	O
therapy	O
of	O
aspirin	O
and	O
a	O
PI3K	O
inhibitor	O
further	O
attenuated	O
tumor	O
growth	O
.	O

In	O
vivo	O
,	O
oncogenic	O
PIK3CA	O
-	O
driven	O
mouse	O
mammary	B:C1458155
tumors	I:C1458155
treated	O
daily	O
with	O
aspirin	O
resulted	O
in	O
decreased	O
tumor	O
growth	O
kinetics	O
,	O
whereas	O
combination	O
therapy	O
of	O
aspirin	O
and	O
a	O
PI3K	O
inhibitor	O
further	O
attenuated	O
tumor	O
growth	O
.	O

In	O
vivo	O
,	O
oncogenic	O
PIK3CA	O
-	O
driven	O
mouse	O
mammary	O
tumors	I:C1458155
treated	O
daily	O
with	O
aspirin	B:C0004057
resulted	O
in	O
decreased	O
tumor	O
growth	O
kinetics	O
,	O
whereas	O
combination	O
therapy	O
of	O
aspirin	O
and	O
a	O
PI3K	O
inhibitor	O
further	O
attenuated	O
tumor	O
growth	O
.	O

In	O
vivo	O
,	O
oncogenic	O
PIK3CA	O
-	O
driven	O
mouse	O
mammary	O
tumors	I:C1458155
treated	O
daily	O
with	O
aspirin	O
resulted	O
in	O
decreased	O
tumor	O
growth	O
kinetics	O
,	O
whereas	O
combination	O
therapy	B:C0087111
of	O
aspirin	O
and	O
a	O
PI3K	O
inhibitor	O
further	O
attenuated	O
tumor	O
growth	O
.	O

In	O
vivo	O
,	O
oncogenic	O
PIK3CA	O
-	O
driven	O
mouse	O
mammary	O
tumors	I:C1458155
treated	O
daily	O
with	O
aspirin	O
resulted	O
in	O
decreased	O
tumor	O
growth	O
kinetics	O
,	O
whereas	O
combination	O
therapy	O
of	O
aspirin	B:C0004057
and	O
a	O
PI3K	O
inhibitor	O
further	O
attenuated	O
tumor	O
growth	O
.	O

In	O
vivo	O
,	O
oncogenic	O
PIK3CA	O
-	O
driven	O
mouse	O
mammary	O
tumors	I:C1458155
treated	O
daily	O
with	O
aspirin	O
resulted	O
in	O
decreased	O
tumor	O
growth	O
kinetics	O
,	O
whereas	O
combination	O
therapy	O
of	O
aspirin	O
and	O
a	O
PI3K	B:C0044602
inhibitor	O
further	O
attenuated	O
tumor	O
growth	O
.	O

Our	O
study	O
supports	O
the	O
evaluation	B:C0220825
of	O
aspirin	O
and	O
PI3K	O
pathway	O
inhibitors	O
as	O
a	O
combination	O
therapy	O
for	O
targeting	O
breast	O
cancer	I:C0678222
.	O

Our	O
study	O
supports	O
the	O
evaluation	O
of	O
aspirin	B:C0004057
and	O
PI3K	O
pathway	O
inhibitors	O
as	O
a	O
combination	O
therapy	O
for	O
targeting	O
breast	O
cancer	I:C0678222
.	O

Our	O
study	O
supports	O
the	O
evaluation	O
of	O
aspirin	O
and	O
PI3K	B:C0044602
pathway	O
inhibitors	O
as	O
a	O
combination	O
therapy	O
for	O
targeting	O
breast	O
cancer	I:C0678222
.	O

Our	O
study	O
supports	O
the	O
evaluation	O
of	O
aspirin	O
and	O
PI3K	O
pathway	O
inhibitors	B:C1254351
as	O
a	O
combination	O
therapy	O
for	O
targeting	O
breast	O
cancer	I:C0678222
.	O

Our	O
study	O
supports	O
the	O
evaluation	O
of	O
aspirin	O
and	O
PI3K	O
pathway	O
inhibitors	O
as	O
a	O
combination	O
therapy	B:C0087111
for	O
targeting	O
breast	O
cancer	I:C0678222
.	O

Our	O
study	O
supports	O
the	O
evaluation	O
of	O
aspirin	O
and	O
PI3K	O
pathway	O
inhibitors	O
as	O
a	O
combination	O
therapy	O
for	O
targeting	O
breast	B:C0678222
cancer	I:C0678222
.	O

